Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Blog | November 07, 2013

Exhaustion applied to patented method where the patentee gave away the "inventive" component used to perform the method for free

Blog | November 07, 2013

Prosecution history estoppel applied where an amendment, though perhaps not necessary to overcome prior art, was not tangential and the equivalent was foreseeable

Blog | November 06, 2013

Third Party Trademarks: Fair Use or Foul?

Blog | November 05, 2013

EDTX Imposes Early, Tight Limits on Asserted Patent Claims and Combinations of Prior Art References

Blog | November 05, 2013

Mobile Medical Apps: FDA Issues Final Guidance

Blog | November 04, 2013

Federal Circuit confines the infringement analysis in generic drug cases to the product as described in the defendant's FDA application

Blog | November 01, 2013

EDTX Denies Plaintiff's MIL Seeking to Exclude Settlement Demands Made in Other Negotiations

Blog | October 28, 2013

CDCA excludes survey opinion

Blog | October 24, 2013

First New "Internationalized" gTLDs Delegated

Blog | October 23, 2013

NDCA excludes damages expert because EMVR not satisfied for smallest salable unit; revised report not allowed

Blog | October 21, 2013

Newest ITC Commissioner sworn in

Blog | October 18, 2013

Shareholder plaintiffs withdraw appeal; exclusive forum selection bylaws are enforceable